At present, 2022 is speeding to a close, and announcements about the resignation of executives of listed pharmaceutical companies have been issued
one after another.
Executives are the core key talents of pharmaceutical companies, what are the reasons for their departure, and what signals do they send to investors?
Over 1000 bits! What signal does the departure of executives of listed pharmaceutical companies send? (Image source: Pharma Network)
Flush data shows that as of November 17, more than 1,400 executives in the A-share biomedical industry left the year, involving 357 enterprises
.
Among them, there are pharmaceutical companies that even have 21 executives leaving within a year, and there are many important positions
such as founder and chairman.
From the perspective of the reasons for the departure of executives, the common reasons for the departure of executives of pharmaceutical companies are mainly "personal reasons", followed by "job transfers"
.
For example, according to the news of the departure of pharmaceutical executives who have left since November, Hao Ruizhi, deputy general manager of YaoTesco, Shi Weijin, deputy general manager of Sinovac Pharmaceutical, Tong Yan, deputy general manager of Cylon Pharmaceutical, Liu Feng, deputy general manager of Thalys Medical, and Cai Shuna, head of finance of Providence Pharmaceutical, all left
due to personal reasons.
From the perspective of the positions left by executives, the deputy general manager and vice president changed frequently during the year, and some deputy general managers of pharmaceutical companies have even changed
many times this year.
For example, Hengrui has successively released the news of the resignation of deputy general managers Tao Weikang, Zou Jianjun, Zhang Yuehong and so on since this year
.
There are also a few executives who have left core technical personnel, including Nuotai Biotech and Jindick Biotechnology
.
According to industry statistics, from the beginning of this year to mid-September, the number of core technical personnel of A-share listed companies left 81, a year-on-year increase of 26.
6%.
The companies with these core technical personnel changes are mainly distributed in pharmaceutical biology, electronics, mechanical equipment, computer and other industries, among which, the number of core technical personnel of pharmaceutical and biological companies is the largest, reaching 20
.
In addition, the board secretaries or financial leaders of some pharmaceutical companies have also recently submitted their resignations, such as Providence Pharmaceutical
.
In this regard, some analysts believe that the board secretary and the chief financial officer generally bear the relevant responsibilities
for the disclosure of important matters of listed companies and major financial reports.
At present, it is the pre-disclosure stage of the fourth quarter results, and the departure of these personnel has also attracted much attention from the market, and the industry expects that with the implementation of the new securities law and the strengthening of securities supervision, the trend of risk-off departures may not weaken
in the short term.
Overall, executive changes are both proactive and passive
.
For executives who actively "leave", it may be to seek better development prospects or avoid business risks
.
From the perspective of the adjustment of the work of pharmaceutical companies, it can also be seen that the pharmaceutical market environment and company ecology behind them are undergoing great changes and have to be changed
.
"With the promotion of policies such as consistency evaluation, centralized procurement and price reduction, and medical insurance fee control, many pharmaceutical companies are under pressure on their profits, and even have operational difficulties, in which case it is reasonable for companies to change senior executives and other methods to improve the current situation
.
"
So, how should investors rationally deal with the resignation of pharmaceutical executives? Some industry insiders believe that for companies where multiple executives resign at the same time and there are no objective or special reasons such as mergers and acquisitions, it may indicate that the executives are not optimistic about the company's future operation, and investors should be vigilant
against such companies.
However, the person also suggested that companies with executive departures should be treated differently, mainly based on the fundamentals of
the company.
If the fundamentals are good and the valuation is not high, it can still be held; If the fundamentals deteriorate, avoidance is the main
thing.
Of course, some companies that have executives leaving due to suspected violations also need to be
treated with caution.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
